OTCMKTS:OASMY Vivesto (OASMY) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free OASMY Stock Alerts $0.05 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.05▼$0.0550-Day Range$0.02▼$0.0552-Week Range$0.00▼$0.02VolumeN/AAverage Volume87 shsMarket Capitalization$8.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartDividendFinancialsSEC FilingsShort InterestStock AnalysisChartDividendFinancialsSEC FilingsShort Interest Get Vivesto alerts: Email Address Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Vivesto Stock (OTCMKTS:OASMY)Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.Read More OASMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OASMY Stock News HeadlinesJanuary 20, 2024 | morningstar.comVivesto AB ADR OASMYAugust 29, 2023 | finance.yahoo.comVivesto AB (OASMY) Stock Historical Prices & Data - Yahoo FinanceMay 12, 2024 | OIC (Ad)[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueJoin us for an exploration of essential volatility concepts in our "Volatility Fundamentals II: Skew & Relative Value" session. OIC® instructor Ken Keating will guide you through important topics that options investors should understand. July 19, 2023 | investing.comOMX Stockholm Pharmaceuticals and Biotechnology GI (SX201030GI)June 4, 2023 | investing.comOMX Stockholm Health Care GI (SX20GI)February 26, 2023 | benzinga.comGlobal Pet Cancer Therapeutics Market Report to 2027 - Featuring Zoetis, AB Science, Karyopharm Therapeutics, Vivesto and Merial Among OthersJanuary 11, 2022 | nasdaq.comOasmia Pharmaceutical AB ADR (OASMY)See More Headlines Receive OASMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivesto and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:OASMY CUSIPN/A CIK1607245 Webwww.oasmia.com Phone(461) 850-5440Fax461-851-0873Employees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,350,000.00 Net MarginsN/A Pretax Margin-654,234.38% Return on Equity-99.73% Return on Assets-91.27% Debt Debt-to-Equity Ratio0.01 Current Ratio4.65 Quick Ratio4.65 Sales & Book Value Annual Sales$100,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book0.28Miscellaneous Outstanding SharesN/AFree FloatN/AMarket Cap$8.95 million OptionableNot Optionable Beta21.67 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Robert Maiorana (Age 64)Head of Accounting & Acting CFO Mr. Urban EkelundIR ManagerMr. John T. Cosby (Age 62)Head of Regulatory Affairs Mr. Dzianis BabrouHead of Product DevelopmentMr. Henrik RönnbergChief Medical Officer of Animal HealthMaria Nilsson HagbergHead of Regulatory AffairsDr. Heidi B. Ramstad (Age 55)Chief Medical Officer Ms. Johanna Rostin (Age 57)Chief Regulatory Officer Ms. Kia Bengtsson (Age 55)Head of Clinical Development Ms. Teresa Fernandez Zafra (Age 37)Head of Preclinical Development & Clinical Operations More ExecutivesKey CompetitorsPhio PharmaceuticalsNASDAQ:PHIOGeoVax LabsNASDAQ:GOVXMateon TherapeuticsOTCMKTS:MATNPhaseBio PharmaceuticalsNASDAQ:PHASAtrecaNASDAQ:BCELView All Competitors OASMY Stock Analysis - Frequently Asked Questions How have OASMY shares performed in 2024? Vivesto's stock was trading at $0.02 on January 1st, 2024. Since then, OASMY stock has increased by 149.5% and is now trading at $0.0499. View the best growth stocks for 2024 here. How do I buy shares of Vivesto? Shares of OASMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OASMY) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivesto AB Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.